We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

13 hedge funds and large institutions have $8.31M invested in Kiora Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $5.44M → $8.31M (+$2.87M)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

35% less funds holding

Funds holding: 20 → 13 (-7)

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
13
Holders Change
-7
Holders Change %
-35%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$196K
2
VF
Virtu Financial
New York
+$30K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$9.23K
4
PAM
Panagora Asset Management
Massachusetts
+$9.23K
5
UBS Group
UBS Group
Switzerland
+$9.23K

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$23K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$22K
3
TSS
Two Sigma Securities
New York
-$17K
4
Millennium Management
Millennium Management
New York
-$14K
5
Jane Street
Jane Street
New York
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$8.03M +$196K +85 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$61K +$6.92K +3 +14%
PAM
3
Panagora Asset Management
Massachusetts
$60K +$9.23K +4 +20%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$46K +$9.23K +4 +29%
VF
5
Virtu Financial
New York
$32K +$30K +13 New
Citadel Advisors
6
Citadel Advisors
Florida
$22K +$4.62K +2 +29%
US Bancorp
7
US Bancorp
Minnesota
$19K – – –
UBS Group
8
UBS Group
Switzerland
$13K +$9.23K +4 +400%
WS
9
Wedbush Securities
California
$9K – – –
Northern Trust
10
Northern Trust
Illinois
$7K – – –
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$6K – – –
LTFS
12
Ladenburg Thalmann Financial Services
Florida
$4K – – –
Morgan Stanley
13
Morgan Stanley
New York
$2K – – –
Barclays
14
Barclays
United Kingdom
– -$23K -14 Closed
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$22K -13 Closed
TSS
16
Two Sigma Securities
New York
– -$17K -10 Closed
Millennium Management
17
Millennium Management
New York
– -$14K -8 Closed
Jane Street
18
Jane Street
New York
– -$5K -3 Closed
RJFSA
19
Raymond James Financial Services Advisors
Florida
– -$5K -3 Closed
Invesco
20
Invesco
Georgia
– -$3K -2 Closed

KPRX Hedge Fund Activity: Q4 2018 in Review

13 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2018, worth a combined $8.31M — up 53% from $5.44M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of KPRX and 1 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 6 added.

The largest buyer was Armistice Capital, adding an estimated $196K. The largest seller was Barclays, exiting entirely with an estimated $23K sold.

  • 13 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2018, down from 20 in Q3 2018.
  • Funds reported $8.31M of Kiora Pharmaceuticals stock for Q4 2018, up 53% quarter-over-quarter.
  • 1 fund opened new Kiora Pharmaceuticals positions in Q4 2018 and 7 closed out, a net change of -6 holders.
  • The largest Kiora Pharmaceuticals buyer in Q4 2018 was Armistice Capital, an estimated $196K added.
  • The largest Kiora Pharmaceuticals seller in Q4 2018 was Barclays, an estimated $23K sold.

Based on aggregated 13F filings for Q4 2018.